Shares of Sage Therapeutics soared 75 percent on Thursday after the company announced positive results in the testing a significant depressive disorder (MDD) treatment.
Sage said in a good let go that 64 percent of individuals achieved MDD remission using the SAGE-217 drug found in the 15th time of treatment.
This can be a second successful drug trial result in as many months for Sage. On Nov. 9, the business said brexanolone – a medication aimed at treating modest and severe postpartum depressive disorder – met its main goal in two late-stage studies. The stock shot up 54.2 percent that time and is up 44.1 percent in the last month.
“These very encouraging info suggest the probable of SAGE-217 in the treating MDD along with other mood-related disorders that people may pursue,” CEO Jeff Jonas said in a declaration. “The positive activity and safety findings of SAGE-217 in MDD support advancing this program into later stage clinical development.”